spinal muscular atrophy (SMA)
Rare disease · 2021–2022
2decisions
1medicine
1carried consumer input
72individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nusinersen Treatment of adult patients (≥19 years of age) with spinal muscular atrophy (SMA) who experienced symptom onset prior to 19 years of age (≤18 years of age),… | Mar 2022 | Recommended with restriction | unclear |
| nusinersen Treatment of adult patients (aged >18 years) with spinal muscular atrophy (SMA) who have experienced signs and symptoms of SMA prior to 19 years of age (≤18… | Jul 2021 | Recommended with restriction | 72 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.